-Company's Goal Is to Lower the Cost of Genome Analysis to $100 In Order To Make Genomic Information Universally Available for Routine Medical Care-
PHILADELPHIA, Feb. 24 /PRNewswire/ -- BioNanomatrix, Inc., a developer of breakthrough whole genome imaging and analysis platforms for biomedical research, molecular diagnostics and personalized medicine, today announced that its low-cost nanofluidic genome analysis technology, along with founder and chief scientific officer Han Cao, Ph.D., has been included in Technology Review magazine's 2009 list of 10 emerging technologies ("the TR10") that will change the way we live and do business. The revolutionary innovations included in this year's TR10 -- each represented by a researcher whose vision and work leads the field -- promise fundamental shifts in areas from energy to health care, computing to communications.
BioNanomatrix is applying its expertise in nanochips, nanodevices and nanosystems to develop its proprietary technology providing comprehensive analysis of genomic and epigenomic information with sensitivity at the single-molecule level. Among its current development efforts is a five-year federally funded project to sequence the human genome in eight hours at a cost of $100.
"We are thrilled that the transformative potential of our nanoscale whole genome analysis technology has been recognized by our inclusion in the 2009 TR10," said Michael Boyce-Jacino, Ph.D., chief executive officer of BioNanomatrix. "By dramatically decreasing the time and cost needed to obtain very accurate and highly informative genomic information, we believe our technology has the potential to greatly increase the utility of genomic data for a wide range of medical and research applications. We also want to acknowledge our scientific colleagues at the NIH and
|SOURCE BioNanomatrix, Inc.|
Copyright©2009 PR Newswire.
All rights reserved